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Abstract
Background: The current study utilized a Bleomycin-induced model of skin fibrosis to investigate the neo-epitope
CO3-610 (KNGETGPQGP), a fragment of collagen III released during matrix metalloproteinase-9 (MMP9) degradation
of the protein, we have previously described as a novel biomarker for liver fibrosis. The aim was to investigate
CO3-610 levels in another well characterised model of fibrosis, to better describe the biomarker in relation to
additional fibrotic pathologies.
Methods: Skin fibrosis was induced by daily injections of Bleomycin to a total of 52 female C3 H mice, while
control mice (n = 28) were treated with phosphate buffered saline (PBS), for 2, 4, 6 or 8 weeks. Skin fibrosis was
evaluated using Visiopharm software on Sirius-red stained skin sections. Urine ELISA assays and creatinine
corrections were performed to measure CO3-610 levels.
Results: CO3-610 levels were significantly higher in Bleomycin-treated vs. PBS-treated mice at each time point of
termination. The mean increases were: 59.2%, P < 0.0008, at 2 weeks; 113.5%, P < 0.001, at 4 weeks; 136.8%, P <
0.0001 at 6 weeks; 157.2%, P < 0.0001 at 8 weeks). PBS-treated mice showed a non-significant increase in CO3-610
levels (mean increase for weeks 2-8 = 1.7%, P = 0.789) CO3-610 levels assayed in urine were statistically
significantly correlated with Western blot analysis showing increased skin fibrosis (P < 0.0001, r = 0.65).
Conclusion: Increased levels in mouse urine of the MMP-9 mediated collagen III degradation fragment CO3-610
were correlated with skin fibrosis progression, suggesting that CO3-610 may be a potential positive biomarker to
study the pathogenesis of skin fibrosis in mice.
Background
The extracellular matrix (ECM) is the major component of
connective tissue. It consists mainly of proteoglycans, gly-
coprotein and collagens, all of which have important and
unique roles in maintaining the physicochemical structure
of tissue [1-3]. Fibrotic skin diseases share a number of
common phenotypic manifestations, particularly the accu-
mulation of collagen, indicating a disturbed balance in
ECM remodelling (ECMR) [4]. Matrix metalloproteinases
(MMPs) play a central role in the proteolytic degradation
of collagens and other extracellular molecules, resulting in
the generation of specific cleavage fragments of proteins
which in turn produce new epitopes. These neo-epitopes
may be used as disease markers in a specific organ or in a
specific disease.
In fibrosis, which may be described as extensive scar
formation, the central pathological change is uncon-
trolled ECM remodelling [5,6]. This remodelling leads
to the accumulation of fibrous (scar) tissue and an over-
all increase in ECM density [7]. Histopathological exam-
ination of biopsies is the traditional gold standard for
diagnosis and staging fibrosis and is of utmost signifi-
cance when evaluating the effect of therapeutic interven-
tion. Biopsy, however, has significant drawbacks. It is
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the length and size of the tissue specimen, which subse-
quently leads to low reproducibility and high intra-
patient variation.
Non-invasive biomarkers of fibrogenesis are available
for diagnosis and follow-up of fibrosis, but their accu-
racy is highly variable and in essence they are not tissue
specific. Collagen type III and its N terminal propeptide
(PIINP) have been shown to be potentially valuable mar-
kers of collagen turnover [8] with significance not only
for liver fibrosis but potentially for fibrotic skin [9].
Several animal models of skin fibrosis have been
developed including models utilising exogenous applica-
tion of growth factors [10] and the chromosome 2
dominant mutation of tight skin (Tsk) [11,12]. However,
the Bleomycin-induced fibrosis model established by
Yamamoto [13-17] is the predominant model of skin
fibrosis and was chosen for the current study. Bleomycin
is an anti-tumor agent due to its ability to inhibit DNA
synthesis. It causes single strand scission of DNA in
vivo and in vitro at specific base sequences. Its ability to
cleave double-stranded DNA requires the presence of
iron and oxygen. It also cleaves RNA to a lesser degree
and in a more highly selective fashion.
T h ea i mo ft h ec u r r e n ts t u d yw a st oi n v e s t i g a t e
whether an ELISA sensitive for a MMP-9 mediated type
III collagen degradation neoepitope, C03-106, would be
useful as a marker of skin fibrosis.
Methods
Animals
80 female C3 H mice were housed at the animal
research facilities at Nordic Bioscience, Beijing, China in
standard type III H cages at 22°C ± 2°C with relative
humidity 50 ± 20% with bedding and nest material. The
animals were kept under conditions of a 12-hour light/
dark cycle, ventilated with filtered non-recycled air.
Their diet consisted of standard food pellets and MilliQ
water for the entire test period. The study was approved
by the Danish animal ethics council regulated by the
Danish ministry of justice (Dyreforsøgstilsynet) (study
approval number: 2008/561-1450).
Study design
In 52 C3 H mice, skin fibrosis was induced by daily
Bleomycin injections into their backs (10 μg, 7 days a
week). Dosing volume was 100 μlw i t ht h eB l e o m y c i n
concentration being 100 μg/mL. 28 mice were injected
with PBS daily into their backs and served as controls.
The animals were divided into 4 groups, each compris-
ing 7 PBS- and 13 Bleomycin-treated mice: Group 1 was
sacrificed after 2 weeks, Group 2 after 4 weeks, Group 3
after 6 weeks, and Group 4 was sacrificed after 8 weeks.
On completion of each study period, and following
14 hours of fasting, the animals were asphyxiated by
carbon dioxide and sacrificed by exsanguinations.
Urine and serum sampling
Urine and serum samples were taken from animals fasted
for at least 14 hours overnight. Samples were collected at
the following time points. All animals: baseline (day 0);
Group 1: Day 9, 16 (termination); Group 2: Day 9, 16, 23,
30 (termination); Group 3: Day 9, 16, 23, 30, 37, 44
(termination); Group 4: Day 9, 16, 23, 30, 37, 44, 51, 58
(termination). Blood samples were taken from the retro-
orbital sinus of the mice under light CO2/O2 anesthesia
at baseline and at termination. Blood was collected in
plain tubes and left at room temperature for 30 minutes
to clot, then centrifuged at 1500 g for 10 minutes. All
clot-free liquid was transferred to a new Eppendorf tube
and centrifuged at 1500 g for 10 minutes. Serum was
then transferred to a clean Eppendorf. Urine and serum
were stored at -80°C in labeled Eppendorf tubes.
Tissue handling
S k i ns e c t i o n sf r o mt h ei n j e c t e da r e aw e r ec a r e f u l l yd i s -
sected, weighed, fixed in 4% formaldehyde for a minimum
of 24 hours, cut into slices and embedded in paraffin. An
additional skin section from the injected area was excised
and stored at -80°C for protein extractions. 5 μm slices
were cut, mounted on glass slides and stained with a com-
bination staining protocol for Sirius red and Alcian blue.
Skin sections were examined histologically for accumula-
tion of collagen and presence of proteoglycans.
Immunohistochemistry
5 μm sections of tissue in paraffin were cut, left for 1 hour
at 60°C, dried overnight at 37°C, and stored at 4°C for later
use. As and when samples were required, they were firstly
heated at 60°C for 1 hour to melt the paraffin. Sections
were then deparaffinized in toluene and rinsed in 99%
ethanol 2 times for 5 minutes each. Slides were left for
20 minutes at room temperature in a 1.05% hydrogen per-
oxide in 99.9% ethanol. Slides were rehydrated in a series
of solutions containing from 96% to 70% ethanol and
rinsed in MilliQ water. Skin sections were pretreated with
citrate buffer (pH 6) in a microwave oven (2 × 5 min at
800 W) and left for 20 minutes at room temperature. Pri-
mary antibodies were diluted according to the manufac-
turer’s (AbCam, Cambridge, UK) guidelines with 1%
bovine serum albumin and left on slides for 30 minutes,
after which they were washed in 0.1% Triton X-100 (Sigma
Aldrich, T8787, St. Louis, Missouri, USA) (2 × 5 min). Sec-
ondary antibody (Polymer-HRP, SS Label, Cat No HK519-
XAK, and BioGenex, California, USA) reactions were
blocked with 5% mouse serum for 1 hour, followed by
incubating the slides for 30 minutes. Slides were washed
again in 0.1% Triton X-100 (2 × 5 min). After a final wash
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last step was to incubate the slide with AEC substrate for
10 minutes. Slides were then rinsed with MilliQ water,
counter-stained with Mayer’s hematoxylin, mounted in
Kaiser and air-dried overnight under air hood. A system
utilizing HistoMark (KPL, Cat No. 70-00-18 & 71-00-19,
Gaithersburg, USA) was also used; however this increased
the cross-reactivity with mouse immunoglobin. Aggrecan,
Biglycan, Versican and Decorin antibodies used for immu-
nohistochemistry were the same as those described for
Western blot analysis in the relevant section below.
Biotinylation of antibodies
1 ml of 1 mg/ml purified antibody in PBS buffer was
transferred to a 4 ml mini-sorb tube, and 110 μlo f1M
NaCO3/NaHCO3 (pH 9.6) was added. 8 μl of 0.1 M bioti-
nylation reagents consisting of 10 mg BxNHS dissolved
in 220 μL DMSO was added and the mixture incubated
at room temperature for 1 hour on and over-end rotation
(12 rpm). The biotinylated antibody was then dialyzed
(Mw cut-off value: 12.000-14.000 D) 5 times against a
minimum of 50 volumes of PBS buffer (p.H 7.4) for
24 hours at 2-8°C. Turbidity was subsequently removed
by sterile filtration using a 0.20 μm filter and the final
volume of the biotinylated antibody was measured on a
spectrophotometer at OD 280 nm, using PBS buffer at
auto zero. 200 μl of biotinylated antibody solution was
finally added to 800 μl buffer and measured.
Protein extractions
Tissue taken from the injected area was pulverized in
liquid nitrogen in a steel mortar. Samples were trans-
ferred into a 1.5 ml Eppendorf tube and left shaking
overnight at 4°C in 0.5 M acetic acid solution containing
a protease inhibitor cocktail (Roche Diagnostics, USA).
The samples were then sonicated using 5 pulses at 60%
amplitude (U50 control, IKA Labortechnik, Staufen,
Germany), left for 2 hours gently shaking at 4°C and
centrifuged for 5 minutes at 13,000 rpm. The superna-
tant was carefully removed, transferred to a new labelled
Eppendorf tube and stored at -80°C.
Densitometry
Densitometry measurements were performed using UN-
SCAN-IT Version 6.1 from Silk Scientific (Orem, Utah
84059, USA), according to the manufacturer’sg u i d e -
lines. Measurements were performed for both CO3-610
and Actin loading controls related reactivity. The densi-
tometry shown for CO3-610 was calculated relative to
the loading control levels.
Histology image analysis
Histology sections stained with Sirius red and Alcian blue
were analysed using Visiopharm software Version 3.2.8.0
(Hørsholm, Denmark). The software allowed for quantifi-
cation of specific tissue areas and measurement of skin
thickness. Images were acquired using Pixelink PL-A623C
microscope digital camera (Pixelink, Ottawa, Canada).
SDS PAGE and Western blots
20 μg of tissue extract was mixed with loading buffer
(Invitrogen LDS 4x, NP0007, California, USA), containing
reducing agent (NP0004, Invitrogen). Samples were loaded
into 4-12% Bis-Tris gradient gel (NP0332BOX, Invitrogen)
and run for 52 minutes at 200V. Proteins were transferred
onto a nitrocellulose membrane using i-Blot transfer sys-
tem (Invitrogen) and blocked with 5% skimmed milk in
Tris buffered Saline (TTBS) overnight at 4°C. The follow-
ing antibodies were used according to the manufacturer’s
suggested dilutions: Beta-Actin antibody (AbCam ab8229,
Cambridge, UK) was used as a loading control,
ELISA CO3-610 Urine Assay
100 μl of Bio CO3-610 (2.5 ng/ml) in PBS-TBE was used
to coat straptavidin plates for 30 minutes at 20°C on a
300 rpm shaker. Excess coater was removed by washing 5
times in washing buffer. 20 μl of each urine sample was
diluted 8 fold in an incubation buffer (10 mM: 400 mM
TRIS-BTB) and was then added to the plates. 100 μlo f
CO3-610 peroxidase conjugated antibody solution
(1:40,000 dilution) was added to the plates and left for
overnight incubation at 4°C, with 300 rpm shaking. Plates
were washed 5 times in washing buffer. 100 μlo fT M B
(Kem-En-Tec A/S, Taastrup, Denmark) was added and
incubated in darkness for 15 minutes at 20°C, on a
300 rpm shaker. The reaction was stopped with the addi-
tion of 100 μl of stop-solution and plates were read on an
ELISA reader at 450 nm, with 650 nm as reference.
Buffers used for ELISA
The buffer used for dissolving the coating peptide con-
sisted of: 40 mM Na2HPO4,1 2H 2O, 7 mM KH2PO4, 137
mM NaCl, 2.7 mM KCl, 25 mM EDTA, 0.1% Tween 20,
1% BSA, 10% sorbitol, pH 7.0. The urine assay contained
400 mM TRIZMA, 0.05% Tween 20, 0.1% BSA, 0.36%
Bronidox L5, and p.H 8.0. Washing buffer was composed
of 25 mM TRIZMA, 50 mM NaCl, and 0.036% Bronidox
L5, 0.1% Tween 20, and the reaction-stopping buffer was
composed of 0.1% H2SO4. ELISA plates used for the
assay development were straptavidin-coated from Roche
(Hvidovre, Denmark) cat.: 11940279. All ELISA plates
were analyzed with the ELISA reader from Molecular
Devices, SpectraMax M, and (CA. USA).
Standards
The standard curve was obtained by serial dilution of
biotinylated CO3-610 for the urine assay. Standard con-
centrations were 0, 0.33, 1, 3, 9, 27, 81 and 162 ng/ml.
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Creatinine levels were measured in each urine sample
using the creatinine assay kit DICT-500 (BioAssay Sys-
tems Hayward, California, USA) Urine creatinine correc-
tions were made to the CO3-610 assay results.
Statistical analysis
Mean values and standard error of the mean (SEM) were
calculated using GraphPad Prism (GraphPad Software,
San Diego, CA, USA) and compared by Student’st w o -
tailed paired t-test (a = 0.05) or by Mann-Whitney
two-tailed non-parametric test, whenever appropriate. The
coefficient of correlation (R
2) and the corresponding
p-value were determined by linear regression. A p-value of
0.05 was considered statistically significant. Bleomycin-
treated groups were compared with PBS-treated groups
for each time point of termination.
Results
Histology image analysis
At the time of sacrifice, skin taken from the injected
area of PBS-treated control animals showed normal
gross morphology, while skin taken from the treated
area of Bleomycin-injected animals showed increased
collagen deposition resulting in increased skin thickness.
The overall mean skin thickness in PBS- and. Bleomy-
cin-treated animals was 11.9 and 19.4 arbitrary units
respectively, representing a 63% increase (Figure 1).
Changes in CO3-610 levels in urine
Bleomycin-treated animals showed significantly higher
levels of the MMP9-generated fragment of type III col-
lagen, CO3-610, in urine than corresponding PBS-
treated groups at the same time point. Mean values at
2 weeks were 8.044 ng/ml vs. 5.051 ng/ml, respectively),
corresponding to an average increase of 59.25%. CO3-
610 levels peaked after 8 weeks of bleomycin treatment.
The PBS-treated group reached a peak mean CO3-610
level of 5.418 ng/ml, while the bleomycin-treated group
reached a mean value 13.94 ng/ml, representing a maxi-
mum mean increase between groups of 157.29% at week
8 (Figure 2). CO3-610 levels measured by ELISA and
Western blot densitometry were found to be signifi-
cantly correlated (Figure 2)
Figure 1 Skin section from a control, PBS-treated mouse at 8 weeks of treatment. (A). Skin section from a bleomycin-treated mouse at 8
weeks of treatment (B). The mean skin thickness increase between control PBS-(n = 7/time point) and bleomycin- (n = 13/time point) treated
mice at 2 weeks was 12.43 vs. 15.4 arbitrary units respectively, P = 0.0029); at 4 weeks, 12.7 vs. 18.6, P = 0.0004; 6 weeks, 13.1 vs. 19.4, P < 0.0001;
and at 8 weeks, 12.5 vs. 21.8, P < 0.0001 (C). Overall mean skin thickness increased between control PBS treated- (n = 28) and bleomycin- (n =
52) treated mice for the 8-week duration of the study (11.9 vs. 19.4 arbitrary units respectively, P < 0.0001). Skin thickness was calculated by
Visiopharm software as an overall number per skin section, rather than by estimating density from pictures.
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mice. The diagram shows the assay result at each time point (n = 7 PBS, n = 13 bleomycin-treated per termination point) and the mean CO3-
610 levels across all time points (n = 28 PBS, n = 52 bleomycin-treated mice). At 2 weeks, (mean PBS 5.05 ng/ml, Bleomycin 8.04 ng/ml) P =
0.0008, 4 weeks (mean PBS 5.68 ng/ml, Bleomycin 12.1 ng/ml) P < 0.0001, 6 weeks (mean PBS 5.66 ng/ml, bleomycin 13.4 ng/ml) P < 0.0001,
8 weeks (mean PBS 5.41 ng/ml, bleomycin 13.9 ng/ml) P < 0.0001 and overall P < 0.0001 (A). CO3-610 Western blots image with control and
bleomycin samples after 2 and 8 weeks treatment, and corresponding beta Actin loading controls (B). CO3-610 densitometry measurements for
all time points (n = 7 PBS and n = 13 Bleomycin treated per termination point) and collective CO3-610 levels (n = 28 PBS and n = 52
bleomycin-treated mice) showing a statistically significant increase of CO3-610 levels (P < 0.0001) (C). CO3-610 levels found in the urine assay
were correlated with skin thickness progression, and therefore total collagen deposition (r = 0.4883, R
2 = 0.2384) (D). The correlation between
CO3-610 levels detected by the ELISA urine assay and Western blot densitometry measurements was statistically significant (r = 0.6528, P <
0.0001) (E).
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In fibrotic lesions, the most abundant molecules in the
ECM are various forms of collagens, in particular types I
and III, as well as a range of proteoglycans. During fibro-
genesis, levels of ECM proteins increase significantly.
Thus, a marker of the turnover of these proteins may be
a potential biomarker not only of skin metabolism but
also turnover of internal tissue related to ECMR. Col-
lagen type I (CO1) is the predominant collagen type and
could be an attractive biomarker target. However, CO1 is
degraded during bone resorption and in the fibrotic liver
[18-22] and thus it is difficult to distinguish the source
when measuring CO1 levels in serum or urine.
The present study demonstrates a potential alternative
to CO1 as a biomarker of fibrosis. We showed that the
MMP9-mediated collagen III (CO3) degradation fragment,
CO3-610, can be measured in urine. Increasing CO3-610
levels were shown to be associated with skin fibrosis in
mice, suggesting that CO3-610 might be a positive bio-
marker to study the pathogenesis of skin fibrosis in this
species. We observed that CO3-610 levels increased by a
mean of 157.29% compared with PBS treated animals fol-
lowing 8 weeks of daily bleomycin injections. CO3-610
levels as measured in the urine assay were significantly
correlated to the extent of skin fibrosis. Detection limits of
CO3-610 were significantly lower than those presented by
Barascuk et al (30) in bile duct-ligated rats. IHC assess-
ment of CO3-610 levels in skin sections could provide
additional evidence of the correlation between CO3-610
and skin fibrosis. However, the main limitation of the cur-
rent study was that despite our persistent attempts to use
CO3-610 and a total collagen III antibody for IHC ana-
lyses on mice tissue, we were unsuccessful because we
added a biotinylation step and a blocking step with mouse
sera. Additional evidence of C03-610 levels in fibrotic liver
sections using IHC and Western blot analyses could sup-
port the above observation.
Skin fibrosis, investigated and validated in the bleomycin
model by histological staining and densitometry analysis
of Western blots, was detected in the bleomycin-treated
groups. The increased skin thickness due to total collagen
deposition in bleomycin compared with the PBS-treated
animals was found to be statistically significant at each
time of termination.
Conclusion
We provide evidence that a MMP9-cleaved collagen III
degradation fragment could be a potential marker for
monitoring skin fibrosis. We describe increased levels in
mouse urine of the MMP-9 mediated collagen III degrada-
tion fragment CO3-610 which were correlated with skin
fibrosis progression, suggesting that CO3-610 may be a
potential positive biomarker to study the pathogenesis of
skin fibrosis in mice. Significantly, this could have an
additional clinical relevance as it could be of value for
monitoring skin fibrosis and ECMR in internal organs
such as the liver. Additional research in well-controlled
clinical settings is needed to further investigate this
finding.
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